Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

Candel Therapeutics, Inc. (CADL) announced that the FDA has granted orphan drug designation to its lead investigational adenovirus immunotherapy candidate, CAN-2409, for the treatment of pancreatic ductal adenocarcinoma (PDAC). Shares of the company rallied 42.8% on Apr 12, following the news.The FDA grants the orphan drug designation to support the development of medicines for rare disorders that affect fewer than 200,000 patients in the United States. The orphan drug designation will grant Candel market e ...